Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents

Published:2016-09 Issue:9 Volume:7 Page:e2365-e2365
ISSN:2041-4889
Container-title:Cell Death & Disease
language:en
Short-container-title:Cell Death Dis

Author:

Klingbeil Olaf,Lesche Ralf,Gelato Kathy A,Haendler Bernard,Lejeune Pascale

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Cell Biology,Cellular and Molecular Neuroscience,Immunology

Link

http://www.nature.com/articles/cddis2016271.pdf

Reference47 articles.

1. Valdespino V, Valdespino PM . Potential of epigenetic therapies in the management of solid tumors. Cancer Manag Res 2015; 7: 241–251.

2. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O et al. Selective inhibition of BET bromodomains. Nature 2010; 468: 1067–1073.

3. Bandopadhayay P, Bergthold G, Nguyen B, Schubert S, Gholamin S, Tang Y et al. BET bromodomain inhibition of MYC-amplified medulloblastoma. Clin Cancer Res 2014; 20: 912–925.

4. Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M, Yang R et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 2014; 510: 278–282.

5. Segura MF, Fontanals-Cirera B, Gaziel-Sovran A, Guijarro MV, Hanniford D, Zhang G et al. BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy. Cancer Res 2013; 73: 6264–6276.

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting apoptosis in clear cell renal cell carcinoma;Biomedicine & Pharmacotherapy;2024-06

2. Tumor suppressive role of the epigenetic master regulator BRD3 in colorectal cancer;Cancer Science;2024-03-17

3. MYC the oncogene from hell: Novel opportunities for cancer therapy;European Journal of Medicinal Chemistry;2024-03

4. Targeting super-enhancer activity for colorectal cancer therapy;American Journal of Translational Research;2024

5. Targeting the epigenetic reader “BET” as a therapeutic strategy for cancer;Bioorganic Chemistry;2023-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3